(VHT) Health Care Shares - Overview
Etf: Pharmaceuticals, Biotechnology, Medical Devices, Healthcare Services
Dividends
| Dividend Yield | 1.74% |
| Yield on Cost 5y | 2.13% |
| Yield CAGR 5y | 11.13% |
| Payout Consistency | 96.1% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 14.6% |
| Relative Tail Risk | 0.58% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.36 |
| Alpha | -2.18 |
| Character TTM | |
|---|---|
| Beta | 0.545 |
| Beta Downside | 0.539 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.91% |
| CAGR/Max DD | 0.46 |
Description: VHT Health Care Shares January 03, 2026
The Vanguard Health Care Index Fund ETF (NYSE ARCA: VHT) follows a pure-indexing strategy that seeks to mirror the performance of its benchmark-a GICS-defined health-care index comprising large, mid-size and small U.S. companies. The fund attempts to hold each constituent in roughly the same proportion as its index weight, thereby delivering broad exposure to the domestic health-care sector with minimal tracking error.
Key metrics as of the latest filing: an expense ratio of 0.10%, top holdings dominated by UnitedHealth Group (~9%), Johnson & Johnson (~6%) and Pfizer (~5%), and sector allocations of roughly 45% pharmaceuticals, 30% health-care services and 25% biotech/medical devices. The health-care sector’s growth is underpinned by an aging U.S. population and historically robust spending growth of about 7% YoY, which together drive earnings expansion for VHT’s constituents.
For a deeper dive into VHT’s risk-adjusted performance and peer comparison, you might explore ValueRay’s analytical tools.
What is the price of VHT shares?
Over the past week, the price has changed by +1.36%, over one month by -0.92%, over three months by +7.59% and over the past year by +9.20%.
Is VHT a buy, sell or hold?
What are the forecasts/targets for the VHT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 313 | 7.5% |
VHT Fundamental Data Overview February 03, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 17.63b USD (17.63b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 17.63b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 17.63b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.92% (E(17.63b)/V(17.63b) * Re(7.92%) + (debt-free company))
Discount Rate = 7.92% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)